Juan María
González Lahoz
Publications dans lesquelles il/elle collabore avec Juan María González Lahoz (70)
2011
-
Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance
Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16
-
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis
Journal of Viral Hepatitis, Vol. 18, Núm. 8, pp. 542-548
2010
-
Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes
Journal of Viral Hepatitis, Vol. 17, Núm. 12, pp. 866-871
-
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649
-
Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial
HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204
-
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring
Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244
2009
-
Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: Influence of HIV infection
Journal of Viral Hepatitis, Vol. 16, Núm. 11, pp. 790-795
-
Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients
HIV Medicine, Vol. 10, Núm. 1, pp. 53-59
2008
-
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785
-
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 200-205
-
Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 699-704
-
Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
AIDS, Vol. 22, Núm. 18, pp. 2535-2537
-
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822
2007
-
Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis
Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 392-395
-
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study
AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241
-
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
AIDS, Vol. 21, Núm. 1, pp. 41-46
-
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
Journal of Infectious Diseases, Vol. 195, Núm. 7, pp. 973-979
-
Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
AIDS, Vol. 21, Núm. 5, pp. 583-588
-
Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
Journal of Infectious Diseases, Vol. 195, Núm. 8, pp. 1181-1183
-
Update on the treatment of chronic hepatitis C in HIV-infected patients
AIDS Reviews, Vol. 9, Núm. 2, pp. 99-113